Biocon Ltd

Biocon Ltd Performance

₹202.3
Day's Price Range
₹208.2
₹191.55
52-Week Price Range
₹388
1 Month Return-9.16 %
3 Month Return-21.66 %
1 Year Return-39.65 %

Analyst Rating

based on 22 analysts

BUY
59.09%
Buy
22.73%
Hold
18.18%
Sell

Based on 22 analysts offering long term price targets for Biocon Ltd. An average target of ₹313.02

Source: S&P Global Market Intelligence

Biocon Ltd Price Movements

  • Biocon moved 2% higher on 23 Mar, 2023

    Biocon share price rose amid value buying. Notably, the stock continued to remain in the F&O ban list which capped the upside.

  • Biocon declined marginally on 21 Mar, 2023

    Biocon share price fell marginally after it came under the F&O ban.

  • Biocon dipped 2% on 20 Feb, 2023

    Biocon share price declined to touch 1-year lows after the share was removed from Nifty Next 50.

  • Biocon dipped 4% on 17 Feb, 2023

    Biocon share price declined after the company reported a 25% yearly decline in net profits to Rs 140 crores for the Oct-Dec 22 period.

Biocon Ltd Valuation

Biocon Ltd in the last 5 years

Lowest (30.85x)

October 1, 2019

Today (63.49x)

March 31, 2023

Highest (118.86x)

September 27, 2018

LowHigh

63.49x

Price to Earnings TTM Ratio

Insights on Biocon Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up
    img

    Mutual Funds have increased holdings from 3.21% to 3.95% in Dec 2022 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich
    img

    Revenue is up for the last 3 quarters, 2.21K Cr → 3.01K Cr (in ₹), with an average increase of 14.0% per quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up
    img

    Retail Investor have increased holdings from 15.18% to 15.73% in Dec 2022 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged
    img

    Promoters holdings remained unchanged at 60.64% of holdings in Dec 2022 quarter

  • imgNO EFFECT

    Against Peers
    img

    In the last 1 year, Syngene International Ltd has given -0.5% return, outperforming this stock by 39.2%

  • imgNO EFFECT

    Against Peers
    img

    In the last 3 years, Vimta Labs Ltd has given 424.4% return, outperforming this stock by 450.3%

  • imgNEGATIVE IMPACT

    FII Holding Down
    img

    Foreign Institutions have decreased holdings from 15.79% to 14.42% in Dec 2022 quarter

  • imgNEGATIVE IMPACT

    Profit Down
    img

    Netprofit is down for the last 4 quarters, 238.6 Cr → -41.8 Cr (in ₹), with an average decrease of 98.7% per quarter

  • imgNEGATIVE IMPACT

    Price Dip
    img

    In the last 1 year, BIOCON stock has moved down by -39.6%

Biocon Ltd Shareholding Pattern

InvestorsHoldings %Prev. 4 periods3M change
Promoter Holdings
60.64%
0.00
Foreign Institutions
14.42%
-8.70
Mutual Funds
3.95%
22.88
Retail Investors
15.73%
3.64
Others
5.26%
1.69

News

National Overseas Scholarship Scheme: Apply to get huge financial help

National Overseas Scholarship Scheme for SC 2023-24 is an initiative of the Minister of Social Justice and Empowerment, Government of India for students... Read more

23 Mar, 2023 07:21 PM

Corporate Announcements

  • Biocon Ltd Earnings Results

    Biocon Ltd’s net profit fell -122.34% since last year same period to ₹-41.8Cr in the Q3 2022-2023. On a quarterly growth basis, Biocon Ltd has generated -189.13% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Biocon Ltd Dividends April,2022

    In the quarter ending June 2022, Biocon Ltd has declared dividend of ₹0.5 - translating a dividend yield of 0.24%.

    Read More about Dividends

Biocon Ltd Company Information

Biocon Ltd is a biopharmaceutical company founded in 1978 by Kiran Mazumdar-Shaw. It is headquartered in Bangalore, India and is one of the top biopharma companies in the world. The company operates in four core areas - biopharmaceuticals, biologics, research services, and clinical research. Biocon's biopharmaceuticals business focuses on biologics and biosimilars, while its biologics business focuses on the discovery, development and commercialization of novel biologics. Its research services include contract research and manufacturing services, while its clinical research business focuses on clinical trials and clinical data management.

Biocon's top products include insulin, monoclonal antibodies, enzymes, and vaccines. Its popular brands include Insugen, Insupen, and Insugen Plus. The company has a strong presence in the Indian market and is expanding its reach to other countries. Biocon has also established its presence in the US, Europe, and Japan.

Biocon Ltd Share Price: ₹206.35 per share as on 31 Mar, 2023 04:01 PM
Biocon Ltd Market Capitalisation: ₹28,004.00Cr as of today
Biocon Ltd Revenue: ₹3,019.7Cr as on December 2022 (Q4 22)
Biocon Ltd Net Profit: ₹-41.8Cr as on December 2022 (Q4 22)
Biocon Ltd Listing date: 04 Jul, 2004
Biocon Ltd Chairperson Name: Kiran Mazumdar Shaw
OrganisationBiocon Ltd
HeadquartersBangalore
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Frequently Asked Questions

Biocon Ltd(BIOCON) share price today is ₹206.35 (last updated 31 Mar, 2023 at 04:01 PM)

  • Today’s highest price of Biocon Ltd(BIOCON) is ₹208.20.
  • Today’s lowest price of Biocon Ltd(BIOCON) is ₹202.30.
  • (last updated 31 Mar, 2023 at 04:01 PM)
Today’s traded volume of Biocon Ltd(BIOCON) is 3884200.
Today’s market capitalisation of Biocon Ltd(BIOCON) is ₹28,004.00Cr.
Biocon Ltd(BIOCON)Price
52 Week High₹388.00
52 Week Low₹191.55
  • (last updated 31 Mar, 2023 at 04:01 PM)
  • Biocon Ltd(BIOCON) share price is ₹206.35 (last updated 31 Mar, 2023 at 04:01 PM). It is down -46.82% from its 52 Week High price of ₹388.00
    Biocon Ltd(BIOCON) share price is ₹206.35 (last updated 31 Mar, 2023 at 04:01 PM). It is up 7.73% from its 52 Week Low price of ₹191.55
    Biocon Ltd(BIOCON)Returns (%)
    1 Day Returns2.36%
    1 Month Returns-9.16%
    1 Year Returns-39.65%
    3 Year Returns-25.88%
    5 Year Returns-31.04%
    Biocon Ltd(BIOCON) share price is ₹206.35 and its price to earning (PE) is 63.49. A high PE ratio indicates that a share price is overvalued, or investors are expecting a high growth rate in the future.